Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

664
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
664
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

619
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
619
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

479
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
479
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

513
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
513
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

633
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
633
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

553
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
553

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?

Circulation·2023
Same author

Insulin resistance is associated with subclinical myocardial dysfunction and reduced functional capacity in heart failure with preserved ejection fraction.

Journal of cardiology·2023
Same author

Hypoxaemia in patients with heart failure and preserved ejection fraction.

European journal of heart failure·2023
Same author

Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.

JACC. Heart failure·2023
Same author

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

JACC. Heart failure·2023
Same author

Update on Atrial Shunt Therapy for Treatment of Heart Failure.

Structural heart : the journal of the Heart Team·2023
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Feb 9, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

801

La hipertensión pulmonar es la hipertensión pulmonar.

Sanjiv J Shah1

  • 1Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. sanjiv.shah@northwestern.edu

JAMA
|October 4, 2012
PubMed
Resumen
Este resumen es generado por máquina.

La hipertensión pulmonar (HP) requiere un diagnóstico cuidadoso, diferenciándola de la hipertensión arterial pulmonar (HAP). El manejo efectivo implica la comprensión de la ecocardiografía, las pruebas invasivas y las estrategias de tratamiento personalizadas para obtener mejores resultados para los pacientes.

Más Videos Relacionados

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

958
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.7K

Videos de Experimentos Relacionados

Last Updated: Feb 9, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

801
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

958
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.7K

Área de la Ciencia:

  • Cardiología Cardiología.
  • Pulmonología Pulmonología.
  • Diagnóstico médico Diagnóstico médico

Sus antecedentes:

  • La hipertensión pulmonar (HP), caracterizada por una presión arterial pulmonar elevada, es prevalente y está relacionada con un aumento de la mortalidad.
  • Los médicos con frecuencia ven a pacientes con síntomas como disnea e insuficiencia cardíaca derecha, que a menudo muestran una presión sistólica elevada en la arteria pulmonar (PASP) en la ecocardiografía.
  • Los vasodilatadores arteriales pulmonares generalmente se prueban en pacientes con hipertensión arterial pulmonar (HAP), pero un PASP elevado por sí solo no confirma la HAP.

Objetivo del estudio:

  • Para resaltar la importancia de diferenciar la HAP de la PH debido a la enfermedad cardíaca izquierda, que es más común.
  • Para enfatizar la necesidad de enfoques diagnósticos precisos, incluida la ecocardiografía y las pruebas hemodinámicas invasivas.
  • Para guiar las estrategias de tratamiento adecuadas para la hipertensión pulmonar y la insuficiencia cardíaca derecha asociada.

Principales métodos:

  • Revisión de los criterios de diagnóstico y las modalidades de imagenología para PH.
  • Análisis de parámetros hemodinámicos invasivos para un diagnóstico preciso.
  • Comparación de estrategias de tratamiento para diferentes tipos de PH.

Principales resultados:

  • La elevación de PASP en la ecocardiografía no es suficiente para el diagnóstico de HAP; las causas secundarias, especialmente la enfermedad cardíaca izquierda, son más frecuentes.
  • Tratar incorrectamente el PH debido a la enfermedad cardíaca izquierda con vasodilatadores puede empeorar los síntomas.
  • La diferenciación precisa entre HAP y PH debido a la enfermedad cardíaca izquierda es crítica para un manejo eficaz.

Conclusiones:

  • El manejo óptimo de la PH requiere una comprensión profunda de la ecocardiografía y las pruebas hemodinámicas invasivas.
  • Distinguir la HAP de la HAP secundaria a la enfermedad cardíaca izquierda es crucial para seleccionar las terapias adecuadas.
  • El desarrollo de estrategias de tratamiento basadas en la evidencia para la HP y la insuficiencia cardíaca derecha sigue siendo un desafío clínico significativo.